このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Kymera Therapeutics 将来の成長

Future 基準チェック /26

Kymera Therapeuticsの収益は年間4.9%で減少すると予測されていますが、年間収益は年間23.8%で増加すると予測されています。EPS は年間増加すると予測されています。自己資本利益率は 3 年後に-91.8% 0.2%なると予測されています。

主要情報

-4.9%

収益成長率

0.2%

EPS成長率

Biotechs 収益成長	24.7%
収益成長率	23.8%
将来の株主資本利益率	-91.8%
アナリストカバレッジ	Good
最終更新日	21 Jun 2024

今後の成長に関する最新情報

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Released Earnings Last Week And Analysts Lifted Their Price Target To US$47.43

Feb 25

Recent updates

Shareholders Will Probably Hold Off On Increasing Kymera Therapeutics, Inc.'s (NASDAQ:KYMR) CEO Compensation For The Time Being

Jun 12

We Think Kymera Therapeutics (NASDAQ:KYMR) Can Easily Afford To Drive Business Growth

May 03

Kymera Therapeutics: Advancing Into Phase 2 With Partner Sanofi - I Still Have Faith

Mar 21

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Released Earnings Last Week And Analysts Lifted Their Price Target To US$47.43

Feb 25

Optimistic Investors Push Kymera Therapeutics, Inc. (NASDAQ:KYMR) Shares Up 39% But Growth Is Lacking

Feb 17

Kymera Therapeutics, Inc.'s (NASDAQ:KYMR) Shares Climb 33% But Its Business Is Yet to Catch Up

Dec 29

We Think Kymera Therapeutics (NASDAQ:KYMR) Needs To Drive Business Growth Carefully

Nov 06

Industry Analysts Just Made A Substantial Upgrade To Their Kymera Therapeutics, Inc. (NASDAQ:KYMR) Revenue Forecasts

Aug 31

Here's Why We're Not Too Worried About Kymera Therapeutics' (NASDAQ:KYMR) Cash Burn Situation

Aug 04

Kymera Therapeutics, Inc.'s (NASDAQ:KYMR) Share Price Not Quite Adding Up

May 21

We're Hopeful That Kymera Therapeutics (NASDAQ:KYMR) Will Use Its Cash Wisely

Apr 16

Companies Like Kymera Therapeutics (NASDAQ:KYMR) Are In A Position To Invest In Growth

Dec 28

Kymera KT-333 gets FDA orphan drug status for blood cancer subtype

Sep 15

Kymera initiated at buy at Jefferies on promise in oncology, autoimmune spaces

Aug 15

Kymera Therapeutics GAAP EPS of -$0.78 misses by $0.08, revenue of $11.51M misses by $3.46M

Aug 09

Here's Why We're Not Too Worried About Kymera Therapeutics' (NASDAQ:KYMR) Cash Burn Situation

Jul 04

業績と収益の成長予測

NasdaqGM:KYMR - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	77	-262	-168	-149	15
12/31/2025	71	-240	-171	-150	18
12/31/2024	51	-206	-194	-157	17
3/31/2024	79	-155	-136	-98	N/A
12/31/2023	79	-147	-137	-103	N/A
9/30/2023	47	-167	-174	-150	N/A
6/30/2023	52	-158	-169	-153	N/A
3/31/2023	47	-159	-163	-157	N/A
12/31/2022	47	-155	-156	-153	N/A
9/30/2022	46	-154	-155	-152	N/A
6/30/2022	57	-139	-157	-155	N/A
3/31/2022	64	-124	-148	-146	N/A
12/31/2021	73	-100	-131	-129	N/A
9/30/2021	70	-79	-113	-111	N/A
6/30/2021	65	-58	54	58	N/A
3/31/2021	49	-48	69	77	N/A
12/31/2020	34	-55	79	88	N/A
9/30/2020	23	-53	90	97	N/A
6/30/2020	9	-57	-52	-47	N/A
3/31/2020	6	-52	-17	-15	N/A
12/31/2019	3	-41	17	18	N/A

アナリストによる今後の成長予測

収入対貯蓄率: KYMR今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: KYMR今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: KYMR今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: KYMRの収益 ( 23.8% ) US市場 ( 8.4% ) よりも速いペースで成長すると予測されています。

高い収益成長: KYMRの収益 ( 23.8% ) 20%よりも速いペースで成長すると予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: KYMR 3 年以内に赤字になると予測されています。

Kymera Therapeutics 将来の成長

Future 基準チェック /26

主要情報

今後の成長に関する最新情報

Consensus EPS estimates upgraded to US$2.90 loss, revenue downgraded

Price target increased by 7.0% to US$51.07

Consensus revenue estimates increase by 45%

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Released Earnings Last Week And Analysts Lifted Their Price Target To US$47.43

Price target increased by 8.3% to US$43.00

Price target increased by 7.3% to US$42.77

Recent updates

Kymera Therapeutics Presents New Clinical Data from the Ongoing Phase 1 Trial of Stat3 Degrader Kt-333 At Eha Annual Meeting

Shareholders Will Probably Hold Off On Increasing Kymera Therapeutics, Inc.'s (NASDAQ:KYMR) CEO Compensation For The Time Being

Kymera Therapeutics Presents New Clinical Data from Ongoing Phase 1 Trial of MDM2 Degrader KT-253 at ASCO Annual Meeting

Kymera Therapeutics, Inc. Presents New Preclinical Data for KT-621, a First-In-Class, Oral STAT6 Degrader at the ATS Annual Meeting

Kymera Therapeutics to Present New Clinical Data from the Ongoing Phase 1 Trial of Stat3 Degrader KT-333 At EHA Annual Meeting

Consensus EPS estimates upgraded to US$2.90 loss, revenue downgraded

We Think Kymera Therapeutics (NASDAQ:KYMR) Can Easily Afford To Drive Business Growth

Kymera Therapeutics, Inc. Provides Business Highlights and Updates on Its Pipeline of Protein Degraders

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Kymera Therapeutics, Inc., Annual General Meeting, Jun 18, 2024

Price target increased by 7.0% to US$51.07

Kymera Therapeutics, Inc Announces Scientific Presentations At the American Association for Cancer Research 2024 Annual Meeting

Kymera Therapeutics: Advancing Into Phase 2 With Partner Sanofi - I Still Have Faith

Kymera Therapeutics Presents Preclinical Data for STAT6 and TYK2 First-In-Class, Oral Degrader Immunology Programs At the American Academy of Dermatology Annual Meeting

New minor risk - Insider selling

Consensus revenue estimates increase by 45%

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Released Earnings Last Week And Analysts Lifted Their Price Target To US$47.43

New major risk - Revenue and earnings growth

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Optimistic Investors Push Kymera Therapeutics, Inc. (NASDAQ:KYMR) Shares Up 39% But Growth Is Lacking

Kymera Therapeutics, Inc. to Report Q4, 2023 Results on Feb 22, 2024

Chief Medical Officer notifies of intention to sell stock

Independent Director notifies of intention to sell stock

Price target increased by 8.3% to US$43.00

Price target increased by 7.3% to US$42.77

New minor risk - Shareholder dilution

Kymera Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $274.999133 million.

Kymera Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $274.999133 million.

Kymera Therapeutics, Inc.'s (NASDAQ:KYMR) Shares Climb 33% But Its Business Is Yet to Catch Up

Kymera Therapeutics, Inc. Presents Interim Results from STAT3 Degrader Phase 1 Clinical Trial at American Society of Hematology Annual Meeting

Kymera Therapeutics Announces First Patient Dosed in Phase 2 Atopic Dermatitis Clinical Trial of KT-474 (SAR444656)p

Kymera Therapeutics, Inc. Announces Publication of Phase 1 Trial Results for KT-474 (SAR444656), a First-In-Class IRAK4 Degrader, in Nature Medicine

Consensus revenue estimates decrease by 18%, EPS upgraded

Consensus revenue estimates decrease by 12%, EPS upgraded

We Think Kymera Therapeutics (NASDAQ:KYMR) Needs To Drive Business Growth Carefully

Kymera Therapeutics, Inc. to Present New Clinical Data from the Phase 1 Trial of STAT3 Degrader KT-333 at the ASH Annual Meeting

Price target decreased by 16% to US$47.47

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Kymera Therapeutics, Inc. Announces First Patient Dosed in Phase 2 Hidradenitis Suppurativa Clinical Trial of KT-474 (SAR444656)

Kymera Therapeutics, Inc. to Report Q3, 2023 Results on Nov 02, 2023

New minor risk - Share price stability

Kymera Therapeutics, Inc. Presents Preclinical Data Demonstrating Activity of MDM2 Degraders in Acute Myeloid Leukemia and Merkel Cell Carcinoma

New major risk - Revenue and earnings growth

Kymera Therapeutics, Inc. Receives U.S. FDA Fast Track Designation for KT-333, a First-in-Class, Investigational STAT3 Degrader for the Treatment of Relapsed/Refractory Cutaneous T-Cell Lymphoma and Relapsed/Refractory Peripheral T-Cell Lymphoma

Industry Analysts Just Made A Substantial Upgrade To Their Kymera Therapeutics, Inc. (NASDAQ:KYMR) Revenue Forecasts

Consensus revenue estimates increase by 19%

New major risk - Revenue and earnings growth

Here's Why We're Not Too Worried About Kymera Therapeutics' (NASDAQ:KYMR) Cash Burn Situation

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Kymera Therapeutics, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Kymera Therapeutics, Inc.(NasdaqGM:KYMR) dropped from Russell Small Cap Comp Value Index

Kymera Therapeutics’ STAT3 Degrader KT-333 and IRAKIMiD Degrader KT-413 Demonstrate Desired Target Knockdown and Safety with Continued Dose Escalation in Ongoing Phase I Clinical Trials

Kymera Therapeutics Announces Updated Clinical Data from the Phase 1 Trials of STAT3 Degrader KT-333 and IRAKIMiD Degrader KT-413

Kymera Therapeutics, Inc. Presents Data Demonstrating Superior Efficacy of Kt-253, A Potent and Selective Heterobifunctional Mdm2 Degrader

Kymera Appoints Jeremy Chadwick as Chief Operating Officer

Kymera Therapeutics, Inc.'s (NASDAQ:KYMR) Share Price Not Quite Adding Up

Kymera Therapeutics, Inc. Presents Clinical Data from the Phase 1 Trial of Irak4 Degrader, KT-474 (Sar444656), At the European Academy of Dermatology and Venereology Symposium

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

We're Hopeful That Kymera Therapeutics (NASDAQ:KYMR) Will Use Its Cash Wisely

Consensus revenue estimates fall by 13%

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Kymera Therapeutics, Inc. to Report Q4, 2022 Results on Feb 23, 2023

Kymera Therapeutics, Inc. Appoints Ellen Chiniara, J.D., as Chief Legal Officer and Corporate Secretary

Companies Like Kymera Therapeutics (NASDAQ:KYMR) Are In A Position To Invest In Growth

Kymera Therapeutics, Inc. Announces Positive Clinical Results from the Patient Cohort Portion of Its KT-474 (IRAK4) Phase 1 Clinical Trial

Kymera Therapeutics, Inc.' Collaborations Demonstrate Therapeutic Potential of STAT3 Degraders in CTCL and IRAKIMiD Combination with BCL-2 Inhibitor in MYD88-Mutant DLBCL at the American Society of Hematology Annual Meeting

Kymera Therapeutics, Inc. Presents Preclinical Data Demonstrating Activity of KT-253, a Selective Heterobifunctional MDM2 Degrader, in Acute Myeloid Leukemia at the American Society of Hematology Annual Meeting

Consensus revenue estimates fall by 20%

Third quarter 2022 earnings: EPS and revenues miss analyst expectations